Managers / Q4 2024 · view latest →
Checkpoint Capital L.P.
CIK 0001977548 · 345 CALIFORNIA STREET, SUITE 600, SAN FRANCISCO, CA, 94104 · 914-355-0570
Summary
Checkpoint Capital L.P. reported $196M in U.S.-listed holdings across 16 positions for Q4 2024.
The portfolio is heavily concentrated: ARGX alone accounts for 29.0% of reported value.
Compared with Q3 2024, the fund opened 2 new positions and exited 2.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 65.7% · $129M
- ADR · 29.0% · $57M
- Other · 5.4% · $11M
Quarter-over-Quarter Changes full breakdown →
vs Q3 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| RVMDREVOLUTION MEDICINES INC | NEW | +210.0K | 210.0K | +$9M | $9M |
| KYMRKYMERA THERAPEUTICS INC | NEW | +77.5K | 77.5K | +$3M | $3M |
| IRONDISC MEDICINE INC | ADDED | +159.5K | 185.0K | +$10M | $12M |
| TRVITREVI THERAPEUTICS INC | ADDED | +834.1K | 1.08M | +$4M | $4M |
| TCRXTSCAN THERAPEUTICS INC | ADDED | +930.6K | 1.76M | +$1M | $5M |
| PTGXPROTAGONIST THERAPEUTICS INC | SOLD OUT | −240.0K | 0 | −$11M | $0 |
| ALLKGUSDALLAKOS INC | SOLD OUT | −650.0K | 0 | −$424,552 | $0 |
| CYTKCYTOKINETICS INC | TRIMMED | −446.8K | 20.0K | −$24M | $940,800 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ARGXARGENX SEhistory → | SPONSORED ADR | 28.95% | $57M | 92.5K |
| 2 | RYTMRHYTHM PHARMACEUTICALS INChistory → | COM | 20.74% | $41M | 728.0K |
| 3 | PHATPHATHOM PHARMACEUTICALS INChistory → | COM | 9.40% | $18M | 2.27M |
| 4 | AXSMAXSOME THERAPEUTICS INChistory → | COM | 7.53% | $15M | 174.8K |
| 5 | IRONDISC MEDICINE INChistory → | COM | 5.97% | $12M | 185.0K |
| 6 | AVADEL PHARMACEUTICALS PLC | COM SHS | 5.37% | $11M | 1.00M |
| 7 | RVMDREVOLUTION MEDICINES INChistory → | COM | 4.67% | $9M | 210.0K |
| 8 | PLRXPLIANT THERAPEUTICS INChistory → | COM | 3.59% | $7M | 535.5K |
| 9 | TCRXTSCAN THERAPEUTICS INChistory → | COM | 2.72% | $5M | 1.76M |
| 10 | CDTXCIDARA THERAPEUTICS INChistory → | COM NEW | 2.60% | $5M | 196.9K |
| 11 | TRVITREVI THERAPEUTICS INChistory → | COM | 2.27% | $4M | 1.08M |
| 12 | STOKSTOKE THERAPEUTICS INChistory → | COM | 1.71% | $3M | 305.4K |
| 13 | SLNOEURSOLENO THERAPEUTICS INChistory → | COM | 1.60% | $3M | 70.0K |
| 14 | KYMRKYMERA THERAPEUTICS INChistory → | COM | 1.59% | $3M | 77.5K |
| 15 | ATYRATYR PHARMA INC | COM NEW | 0.80% | $2M | 432.6K |
| 16 | CYTKCYTOKINETICS INC | COM NEW | 0.48% | $940,800 | 20.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $279M | 8 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $320M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $298M | 10 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $215M | 8 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $182M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $196M | 16 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $202M | 16 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $166M | 16 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $150M | 17 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $165M | 19 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.